Skip to main content
SpringerLink
Log in

Adjuvant Chemotherapy of Breast Cancer

Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1 – 3, 1984

  • Book
  • © 1984

Overview

Editors:
  1. Hans-Jörg Senn

    1. Medizinische Klinik C, Kantonsspital St. Gallen, St. Gallen, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Recent Results in Cancer Research (RECENTCANCER, volume 96)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (30 chapters)

  1. Front Matter

    Pages I-XIII
    Download chapter PDF

  2. Scientific Basis of Adjuvant Chemotherapy in Breast Cancer

    1. The Preclinical Scientific Basis for Adjuvant Chemotherapy in Breast Cancer

      • D. P. Griswold Jr., W. R. Laster Jr., M. W. Trader, D. J. Dykes
      Pages 1-7

    2. The Clinical Scientific Basis of Adjuvant Chemotherapy in Breast Cancer

      • B. Fisher
      Pages 8-17

    3. Molecular and Cellular Mechanisms Underlying Ineffective Cancer Chemotherapy

      • M. F. Rajewsky, N. Huh
      Pages 18-29

    4. Impact of Early Detection of Breast Cancer on Adjuvant Chemotherapy

      • W. H. Hartmann
      Pages 30-33

    5. Contribution of Prognostic Factors to Adjuvant Chemotherapy in Breast Cancer

      • G. Bonadonna, P. Valagussa
      Pages 34-45

    6. Review: Scientific Basis of Adjuvant Chemotherapy in Breast Cancer

      • D. P. Griswold
      Pages 46-47

  3. Experience of Randomized Trials with Surgical Controls

    1. Scandinavian Trials with a Short Postoperative Course Versus a 12-Cycle Course

      • R. Nissen-Meyer, H. Høst, K. Kjellgren, B. Månsson, T. Norin
      Pages 48-54

    2. A Brief Overview of Findings from NSABP Trials of Adjuvant Therapy

      • B. Fisher, E. R. Fisher, C. Redmond, Participating NSABP Investigators
      Pages 55-65

    3. CMF Adjuvant Programs at the Milan Cancer Institute

      • G. Bonadonna, A. Rossi, G. Tancini, P. Valagussa, U. Veronesi
      Pages 66-73

    4. A Controlled Trial of Adjuvant Chemotherapy with Melphalan Versus Cyclophosphamide, Methotrexate, and Fluorouracil for Breast Cancer

      • A. Howell, R. D. Rubens, H. Bush, W. D. George, J. M. T. Howat, D. Crowther et al.
      Pages 74-89

    5. Adjuvant Chemoimmunotherapy with LMF + BCG in Node-Negative and Node-Positive Breast Cancer: 8 Year Results

      • H. J. Senn, W. F. Jungi, R. Amgwerd, E. Hochuli, J. Ammann, G. Engelhart et al.
      Pages 90-101

    6. Ludwig Breast Cancer Trial LBCS III: Chemo- and Endocrine Adjuvant Treatment in Postmenopausal Patients

      • R. D. Gelber
      Pages 102-109

    7. Postmenopausal Node-Positive Comparison of Observation with CMFP and CMPF + Tamoxifen Adjuvant Therapy: An Eastern Cooperative Oncology Group Trial

      • D. C. Tormey, S. G. Taylor IV, R. Gray, J. E. Olson
      Pages 110-116

    8. Adjuvant Systemic Therapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group’s Trials of Cyclophosphamide or CMF in Premenopausal and Tamoxifen in Postmenopausal Patients

      • H. T. Mouridsen, C. Rose, H. Brincker, S. M. Thorpe, F. Rank, K. Fischerman et al.
      Pages 117-128

  4. Experience of Non-Randomized Trials with Historical or Mached Surgical Controls

    1. FAC + BCG as Adjuvant Therapy in Breast Cancer: An 8-Year Update

      • G. R. Blumenschein, A. U. Buzdar, G. N. Hortobagyi
      Pages 129-132

    2. Current Results of the University of Arizona Adjuvant Breast Cancer Trials (1974–1984)

      • S. E. Jones, R. J. Brooks, B. J. Takasugi, H. S. Garewal, G. F. Giordano, S. J. Ketchel et al.
      Pages 133-140

    3. Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer

      • A. U. Buzdar, T. L. Smith, C. E. Marcus, G. N. Hortobagyi, G. R. Blumenschein
      Pages 141-147

    4. The Use of a Natural History Data Base to Compare Outcome Among Several Trials of Adjuvant Chemotherapy for Stage II Breast Cancer

      • S. E. Jones, T. E. Moon
      Pages 148-154
Back to top

Keywords

About this book

H.-J. Senn Adjuvant Chemotherapy (ACT) of breast cancer has now emerged as one of the controversial su):>jects in clinical and also experimental oncology. Driven by growing frustration about stagnating cure rates in breast cancer [1,4] and stimulated by elegant demonstration of highly curative effects of adjuvant systemic therapy in animal models [6, 11] and in several childhood neoplasias [15], researchers introduced ACT to the primary treatment of breast cancer with great hope some 15 years ago. After a first wave of isolated "historic" trials with generally limited but in one case remarkable success [5, 9], a second generation of ACT studies was initiated by NSABP investigators and oncology centers in Europe [2, 6, 13]. These trials were well conducted statistically and diagnostically, and all in the early 1970s included a surgical control arm. Early and intermediate beneficial effects on relapse-free survival (RFS) after 2-3 years median observation time then prompted a whole series of ACT studies in breast cancer. These "third-gener­ ation" studies usually regarded some positive influence of ACT as a given fact, dropping surgical control regimens and comparing different ACT regimens, hopefully in a prospective, randomized way 1984 Fig. 1. The mushrooming of adjuvant studies in breast cancer XII Introduction [reviews in 3, 14]. The "mushrooming" of ACT studies in breast cancer during the last 10 and especially 5 years is demonstrated in Fig. 1, and it gets really cumbersome even for the insider to keep on top of the multitude of sometimes conflicting data.

Editors and Affiliations

  • Medizinische Klinik C, Kantonsspital St. Gallen, St. Gallen, Switzerland

    Hans-Jörg Senn

Bibliographic Information

  • Book Title: Adjuvant Chemotherapy of Breast Cancer

  • Book Subtitle: Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1 – 3, 1984

  • Editors: Hans-Jörg Senn

  • Series Title: Recent Results in Cancer Research

  • DOI: https://doi.org/10.1007/978-3-642-82357-2

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1984

  • Softcover ISBN: 978-3-642-82359-6Published: 15 December 2011

  • eBook ISBN: 978-3-642-82357-2Published: 06 December 2012

  • Series ISSN: 0080-0015

  • Series E-ISSN: 2197-6767

  • Edition Number: 1

  • Number of Pages: XIV, 246

  • Topics: Gynecology, Oncology, Pharmacology/Toxicology, General Surgery

Publish with us

Policies and ethics

Back to top

Search

Navigation